ABUS vs GM · P/E 5.4, rev $6.2M vs P/E 7.5, rev $185.02B
Arbutus Biopharma Corp (ABUS) versus General Motors Company (GM) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
General Motors Company (GM) is a auto manufacturers company listed on US. It is led by Mary Barra.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported GM revenue for 2025-12-31 was $185.02B. Net income was $2.70B. Revenue was down 1.3% from 2024-12-31 to 2025-12-31. GM currently screens at market cap $51.33B and trailing P/E 7.5.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. GM currently screens at market cap $51.33B and trailing P/E 7.5.
Not investment advice. Open the ABUS and GM stock pages for the full models.
Not investment advice.